category,datetime,headline,id,image,related,source,summary,url
company,1769212200,AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term.,138229884,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.",https://finnhub.io/api/news?id=a4ab0ce55c9fa57739bd1a7174b888d2534b2fdd06d55615823a44b039d30a87
company,1769198805,Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments,138229409,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone. Many investors are asking the same question right now. The stock has had mixed returns, with a 3% decline over the last 7 days, a 1.2% gain over the last 30 days, a 2.8% gain year to date, and a 2.4% decline over the last year. The 3-year and 5-year returns sit at a 13.7% decline and a 7.6% gain respectively. Recent headlines around Bristol-Myers Squibb have focused on...",https://finnhub.io/api/news?id=186eba1d518b58365d949d2676cb39cb3b7899e707020e501fd8e4ce744f453e
company,1769191913,"Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 25",138229764,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,BMY,SeekingAlpha,"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.",https://finnhub.io/api/news?id=51cad26e98a55cff634e728377ee94ee04cf1e5384eb442f6922079bdc07e397
company,1769191500,Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?,138228445,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",https://finnhub.io/api/news?id=921ed78dba5a3de16564bf3d9a0f6185fc07cb3cdabc7269749e54bbca782115
company,1769183564,Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion,138229056,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254082934/image_2254082934.jpg?io=getty-c-w1536,BMY,SeekingAlpha,BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market. Read the latest analysis on the stock here.,https://finnhub.io/api/news?id=c5cb0fe2ef5441f695f490a111b43342cb06a59fa7e90d0f43e2ca5f30753f8e
company,1769181082,A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results,138225575,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Bristol Myers Squibb (BMY) is back in focus after two key updates: a new AI lung cancer screening agreement with Microsoft, and positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. See our latest analysis for Bristol-Myers Squibb. Those AI and cardiology updates come after a busy start to 2026, including oncology focused deals like the new Janux Therapeutics agreement. They follow a 90 day share price return of 25.35% against a weaker 1 year total...",https://finnhub.io/api/news?id=cf485bfeb86866e131e7444069e69f6fc146beed2f784bc853309e6245a5e63f
company,1769170680,"JANX Enters Global Oncology Collaboration With BMY, Stock Rises",138224856,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.",https://finnhub.io/api/news?id=b75d7e2fb0d5805d0c863a4bbfa8b099c51cffca1b1ff6ce60c39e6419ec31f8
company,1769149800,"AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",138222072,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772
